Pipeline

Ryvu Therapeutics is advancing a broad pipeline by addressing emerging targets in oncology.

Our pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinase, synthetic lethality, and immuno-oncology pathways.

Clinical Projects

  • Program/ Target Name
  • Indication
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Partner
  • Anticipated
    Milestones
  • RVU120
    CDK8/19
    • R/R AML (RIVER-81, combination theraphy)

    • Initial Phase II data in Q4 2024​

    • Hematologic Malignancies (AML/HR-MDS, LR-MDS, MF) (RIVER-52, monotherapy)

    • Complete Ph I data in 2Q24
      Initial Ph II data in 4Q24      ​

    • Other Hematology ​ (LR-MDS, MF)

    • Initiation of Phase II in mid-2024

    • Solid Tumors

    • Complete Ph I & Translational Studies in 2024​

  • SEL24 (MEN1703)
    PIM/FLT3
    • DLBCL

    • Initiation of Ph II in mid-2024​

Discovery & Preclinical Projects

  • Program/ Target Name
  • Indication
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Partner
  • Anticipated
    Milestones

Synthetic Lethality

  • PRMT5
    • Solid tumors

    • IND-enabling
      studies in 2024

  • WRN
    • Solid tumors

    • Development Candidate
      in 2024

  • NOVEL TARGETS
    • ONCOLOGY

Immuno-oncology

  • STING Standalone
    • Solid tumors
  • STING ADC
    • ONCOLOGY
  • HPK1
    • Solid tumors

 

  • Immune Modulation Research Collaboration (Multi-Target)

 

  • Discovery Collaboration